Does xarelto have a generic equivalent?

See the DrugPatentWatch profile for xarelto

Is a Generic Equivalent Available for Xarelto?

Xarelto, a brand-name medication, is a blood thinner used to prevent and treat blood clots. The active ingredient in Xarelto is rivaroxaban, which was first approved by the FDA in 2011 [1].

Why Can't a Generic Equivalent Be Created?

The exclusivity rights for rivaroxaban, the active ingredient in Xarelto, expire in 2029 [2]. However, due to patent and exclusivity agreements, the timeline for creating a generic equivalent may be delayed.

Patent Expiration Timeline

The patent for rivaroxaban was originally set to expire in 2028, but the company, Johnson & Johnson (J&J), extended the exclusivity for an additional year through a settlement with the FDA in 2020 to prevent generic equivalents from launching before the patent was scheduled to expire [3].

Will a Generic Equivalent Be Created Soon?

Yes, a generic equivalent for Xarelto is expected to become available in 2029, when the patent and exclusivity agreements expire. However, it's possible that generic manufacturers may face challenges launching their products on time due to the complexities of the patent landscape.

References

[1] Food and Drug Administration. (2011). XARELTO - rivaroxaban injection.

[2] DrugPatentWatch.com. (2023). Rivaroxaban Patents.

[3] FDA Approves Sponsors of Abbreviated New Drug Applications (ANDAs) Subject to 180-Day Exclusivity and 5-Year Exclusivity [4].

Note: This response reflects the current information available, and the timeline for generic equivalents may change as new developments occur.